Suppr超能文献

卵巢透明细胞癌患者的分期淋巴结切除术

Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

作者信息

Mueller Jennifer J, Holzapfel Marie, Han Chan H, Santos Kevin, Gunderson Camille, Moore Kathleen, Erickson Britt, Leath Charles A, Diaz Elena, Walsh Christine, Wethington Stephanie L, Dejbakhsh Sheila Z, Barakat Richard R, Gardner Ginger J, Hyman David M, Soslow Robert A, Leitao Mario M

机构信息

*Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; †Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; ‡University of Oklahoma Health Sciences Center, Oklahoma City, OK; §Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL; ∥Department of Obstetrics and Gynecology, Weill Cornell Medical Center, New York, NY; ¶Department of Medicine, Weill Cornell Medical Center, New York, NY; #Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; and **Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY.

出版信息

Int J Gynecol Cancer. 2016 Jan;26(1):120-4. doi: 10.1097/IGC.0000000000000559.

Abstract

OBJECTIVE

The purpose of this study was to assess the rate of lymph node (LN) metastasis in comprehensively staged ovarian clear cell carcinoma (OCCC) clinically confined to the ovary and determine factors associated with LN metastasis.

METHODS

We identified all cases of OCCC treated at 4 institutions from January 1994 through December 2011. We included cases with disease grossly confined to the ovary that had surgical staging performed, including at least 10 LNs sampled. Clinical and pathologic data were abstracted from electronic medical records, and a deidentified data set was compiled and processed at a single institution. Factors potentially associated with LN metastasis were tested. Appropriate statistical tests were performed.

RESULTS

We identified 145 eligible cases that met the criteria for this analysis. Median age was 52.9 years (range, 30-81 years), and median total LN count was 19 (range, 10-74). Seven (4.8%) of 145 comprehensively staged cases had LN metastasis; 6 of these cases (4.1%) were isolated metastasis. Cytologic washings, peritoneal, omental, and fallopian tube involvement were not associated with nodal metastasis. Cases with ovarian surface involvement and positive cytology had a 37.5% incidence of LN positivity, which was statistically meaningful when compared with all other cases (P = 0.003).

CONCLUSIONS

Women who underwent comprehensive staging for clinical stage I OCCC had an LN metastasis rate of 4.8%. The subgroup of cases with both ovarian surface involvement and positive cytology had the highest incidence of LN metastasis. This may influence clinical decision making on whether to perform lymphadenectomy in patients with incidental OCCC found after salpingo-oophorectomy.

摘要

目的

本研究旨在评估临床局限于卵巢的综合分期卵巢透明细胞癌(OCCC)的淋巴结(LN)转移率,并确定与LN转移相关的因素。

方法

我们确定了1994年1月至2011年12月在4家机构接受治疗的所有OCCC病例。我们纳入了疾病大体局限于卵巢且进行了手术分期的病例,包括至少采集了10个LN样本。从电子病历中提取临床和病理数据,并在单一机构汇编和处理去识别化的数据集。对可能与LN转移相关的因素进行了测试。进行了适当的统计检验。

结果

我们确定了145例符合本分析标准的合格病例。中位年龄为52.9岁(范围30 - 81岁),中位LN总数为19个(范围10 - 74个)。145例综合分期病例中有7例(4.8%)发生LN转移;其中6例(4.1%)为孤立转移。细胞学冲洗液、腹膜、网膜和输卵管受累与淋巴结转移无关。卵巢表面受累且细胞学阳性的病例LN阳性发生率为37.5%,与所有其他病例相比具有统计学意义(P = 0.003)。

结论

接受临床I期OCCC综合分期的女性LN转移率为4.8%。卵巢表面受累且细胞学阳性的病例亚组LN转移发生率最高。这可能会影响对输卵管卵巢切除术后偶然发现的OCCC患者是否进行淋巴结清扫术的临床决策。

相似文献

1
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
Int J Gynecol Cancer. 2016 Jan;26(1):120-4. doi: 10.1097/IGC.0000000000000559.
2
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
Gynecol Oncol. 2011 Sep;122(3):536-40. doi: 10.1016/j.ygyno.2011.05.001. Epub 2011 Jun 1.
5
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.
Int J Clin Oncol. 2018 Oct;23(5):930-935. doi: 10.1007/s10147-018-1280-9. Epub 2018 Apr 20.
7
Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma.
J Gynecol Oncol. 2018 Mar;29(2):e19. doi: 10.3802/jgo.2018.29.e19. Epub 2017 Dec 11.
8
Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
Gynecol Oncol. 2015 Feb;136(2):198-204. doi: 10.1016/j.ygyno.2014.12.006. Epub 2014 Dec 10.
9
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.
Ann Surg Oncol. 2017 Sep;24(9):2720-2726. doi: 10.1245/s10434-017-5919-y. Epub 2017 Jun 12.
10

引用本文的文献

1
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae325.
3
The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
World J Surg Oncol. 2024 Jan 29;22(1):37. doi: 10.1186/s12957-024-03324-6.
4
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Int J Gynecol Cancer. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935.
5
Prognostic significance of the number of removed lymph nodes according to FIGO stage in ovarian clear cell carcinoma.
Mol Clin Oncol. 2021 Dec;15(6):263. doi: 10.3892/mco.2021.2425. Epub 2021 Oct 25.
6
7
Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
J Cancer. 2021 Feb 22;12(8):2295-2316. doi: 10.7150/jca.53395. eCollection 2021.
8
Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience.
Gynecol Oncol Rep. 2019 Dec 29;31:100533. doi: 10.1016/j.gore.2019.100533. eCollection 2020 Feb.
9
Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.
Medicine (Baltimore). 2018 May;97(21):e10881. doi: 10.1097/MD.0000000000010881.
10
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.
Int J Clin Oncol. 2018 Oct;23(5):930-935. doi: 10.1007/s10147-018-1280-9. Epub 2018 Apr 20.

本文引用的文献

2
Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
Gynecol Oncol. 2013 Nov;131(2):404-9. doi: 10.1016/j.ygyno.2013.08.029. Epub 2013 Sep 1.
4
Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study.
Ann Surg Oncol. 2012 Nov;19(12):3849-55. doi: 10.1245/s10434-012-2439-7. Epub 2012 Jun 16.
5
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Int J Gynecol Cancer. 2012 May;22(4):573-8. doi: 10.1097/IGC.0b013e31823fd413.
6
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
Gynecol Oncol. 2011 Sep;122(3):536-40. doi: 10.1016/j.ygyno.2011.05.001. Epub 2011 Jun 1.
7
The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.
J Obstet Gynaecol Res. 2010 Oct;36(5):1023-30. doi: 10.1111/j.1447-0756.2010.01274.x.
8
Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer.
Int J Gynecol Cancer. 2010 Apr;20(3):341-5. doi: 10.1111/IGC.0b013e3181cf6271.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验